Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
Tim Heise
Leo Seman
Sreeraj Macha
Peter Jones
Alexandra Marquart
Sabine Pinnetti
Hans J. Woerle
Klaus Dugi
机构：
[1] Profil Institut für Stoffwechselforschung GmbH,
[2] Boehringer Ingelheim Pharmaceuticals,undefined
[3] Inc.,undefined
[4] With Confidence Ltd.,undefined
[5] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[6] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[7] Boehringer Ingelheim GmbH,undefined
来源：
Diabetes Therapy | 2013年 / 4卷
关键词：
BI 10773; Diabetes; Empagliflozin; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：331 / 345
页数：14
相关论文
共 50 条
  • [41] Pharmacokinetics, pharmacodynamics, and tolerability of multiple doses of alogliptin benzoate (SYR-322), a dipeptidyl peptidase-IV inhibitor, in patients with type 2 diabetes
    Christopher, Ronald
    Covington, Paul
    Davenport, Michael
    Fleck, Penny
    Mekki, Qais
    Wann, Elisabeth
    Karim, Aziz
    DIABETES, 2007, 56 : A133 - A133
  • [42] Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
    Iwamoto, Kazuya
    Nasu, Risa
    Yamamura, Ayuko
    Kothare, Prajakti A.
    Wolka, Anne M.
    Linnebjerg, Helle
    DIABETES, 2009, 58 : A163 - A163
  • [43] Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
    Heise, Tim
    Jordan, Jens
    Wanner, Christoph
    Heer, Martina
    Macha, Sreeraj
    Mattheus, Michaela
    Lund, Soren S.
    Woerle, Hans J.
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2016, 38 (10) : 2265 - 2276
  • [44] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
    Sarashina, Akiko
    Koiwai, Kazuki
    Seman, Leo J.
    Yamamura, Norio
    Taniguchi, Atsushi
    Negishi, Takahiro
    Sesoko, Shogo
    Woerle, Hans J.
    Dugi, Klaus A.
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (03) : 213 - 219
  • [45] Evaluation of GSK1292263, a Novel GPR119 Agonist, in Type 2 Diabetes Mellitus (T2DM): Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses
    Nunez, Derek J.
    Bush, Mark A.
    Collins, David A.
    Mcmullen, Susan L.
    Feldman, Paul L.
    Jackson, Tymissha D.
    Ross, Sean A.
    DIABETES, 2011, 60 : A273 - A273
  • [46] Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
    He, Xuemei
    Gao, Xin
    Xie, Panpan
    Liu, Yuan
    Bai, Wenjing
    Liu, Yue
    Shi, Aixin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 2967 - 2980
  • [47] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subjects
    Wang, Shining
    Chen, Grace
    Uz, Tolga
    Affinito, John
    NEUROLOGY, 2018, 90
  • [48] Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (02) : 211 - 223
  • [49] Pharmacokinetics, pharmacodynamics, safety and tolerability of single dose exenatide in very elderly patients (≥75 years) with type 2 diabetes
    Linnebjerg, H.
    Kothare, P. A.
    Seger, M.
    Mitchell, M.
    DIABETOLOGIA, 2009, 52 : S308 - S308
  • [50] Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus
    Cui, Yi Min
    Guo, Xiao Hui
    Zhang, Dong Mei
    Tham, Lai San
    Tang, Cheng Cai
    Mace, Kenneth
    Linnebjerg, Helle
    JOURNAL OF DIABETES, 2013, 5 (02) : 127 - 135
12345